The FDA has approved Exdensur depemokimab-ulaa as an add-on maintenance therapy for severe asthma in patients aged 12 and older, supported by Phase III SWIFT trial data showing significant reductions ...

Examine how evolving sourcing strategies, functional standardization, and system choices can help sponsors support sites more ...

In today’s ACT Brief, we examine new survey data revealing what patients value most in remote clinical trials, break down ...

This case study highlights Quest Diagnostics' successful and cost-effective patient recruitment for The Michael J. Fox Foundation's Parkinson's study. By using its extensive patient network, Quest ...

New survey data show a strong patient preference for fully remote clinical trials, underscoring how convenience, intuitive technology, and FDA-cleared digital tools are reshaping enrollment and ...

In today’s ACT Brief, we close out our McKinsey interview series with a look at how AI could transform clinical trials end to ...

Learn how clinical operations leaders can build technology adoption, transform workflows, and cultivate digitally savvy ...

This datasheet illustrates how Quest Diagnostics' extensive de-identified lab data can be leveraged to accelerate and optimize clinical trials for Chronic Kidney Disease (CKD). Researchers can use ...

Gilead's ARTISTRY-2 trial shows BIC/LEN is non-inferior to Biktarvy in virologically suppressed adults with HIV, with no new safety signals. ARTISTRY-2's design involved a randomized, double-blind ...

In today’s ACT Brief, we look at new evidence showing how targeted training can build research readiness at community cancer ...

Discover how remote assessments, wearables, and digital technologies can decentralize data collection, reduce patient burden, and enable trials to reach more diverse and representative populations.